Compare Royal Caribbean Cruises Ltd (RCL) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs Tango Therapeutics Inc. — how do they compare? Royal Caribbean Cruises Ltd trades at $276.77 (market cap $75.29B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 20.1× Tango Therapeutics Inc.'s market cap, and Royal Caribbean Cruises Ltd pays a 2.13% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royal Caribbean Cruises Ltd for 85 Days and Tango Therapeutics Inc. for 0 Days on average.
| RCL | TNGX | |
|---|---|---|
Market Cap | $75.29B | $3.75B |
Volume | 1,401,290 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $348.03 | $32.90 |
52-Week Low | $230.30 | $7.50 |
Typical Hold Time | 85 Days | 0 Days |
Enterprise Value | $97.93B | $2.77B |
Dividend Yield | 2.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $274.33, down 2.26% today, with a bullish technical signal and strong fundamental recovery. The stock shows robust earnings momentum with Q1 and Q2 2026 beats, while Q3 expectations are high at $6.38 EPS. Revenue growth accelerated from $8.8B in 2022 to $17.9B in 2025, with net income margins improving to 23.54%. Recent news highlights the $3B Sandals resort acquisition as a strategic expansion beyond cruising.
RCL presents a compelling growth story with analyst consensus at Buy (53% of ratings) and a $344.17 price target offering 25% upside. Key risks include execution of the Sandals integration, fuel cost volatility ($1.34B projected for 2026), and high debt levels despite improving leverage. The stock's valuation at 17.4x P/E appears reasonable given 45% ROE and positive cash flow trends.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
